Iovance

IOVA NASDAQ
20.95
+0.93
+4.65%
盘后: 20.95 0 0.00% 17:58 08/16 EDT
开盘
20.22
昨收
20.02
最高
21.15
最低
20.10
成交量
109.47万
成交均量(3M)
177.69万
52周最高
26.59
52周最低
7.26
换手率
0.88%
市值
25.94亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Iovance IOVA股票价格,Iovance股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Iovance Biotherapeutics, Inc., formerly Lion Biotechnologies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. The Company's lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients' tumors, for the treatment of metastatic melanoma. As of December 31, 2016, it had an on-going Phase II clinical trial of its lead product candidate, LN-144, TIL for the treatment of metastatic melanoma. The Company is developing LN-145 to treat cervical and head and neck cancers. It is collaborating with the National Cancer Institute to evaluate unmodified TIL in other solid tumor indications, such as ocular melanoma, bladder, breast and lung cancer. It is collaborating with the NCI to evaluate TIL in combination with the checkpoint inhibitor, Keytruda.
展开 >

最近浏览

名称
价格
涨跌幅